Αποτελέσματα Αναζήτησης
Treatment for co-occurring disorders may be indicated for the many women with AUD who present with additional mental health concerns. Interventions that address the co-occurrence of AUD with trauma and PTSD, mood disorders, and borderline personality disorder may be especially relevant for women.
15 Μαρ 2021 · The Current Situation for Medication-Assisted Treatment of Alcohol Use Disorder. The FDA's approved medication-assisted treatment MATs for AUD are Antabuse, Campral, and Naltrexone.
Treatment with baclofen (30 mg/day, open-label) reduced alcohol consumption and severity of alcohol dependence in alcohol-dependent individuals with alcohol-related liver problems. [ 45 ] Treatment with baclofen (50 mg/day) was not superior to placebo in reducing alcohol drinking or craving in alcohol-dependent individuals.
20 Μαΐ 2020 · The FDA has approved three medications for alcohol use disorder: naltrexone, acamprosate, and disulfiram. Additionally, other medications including gabapentin, baclofen, topiramate, and ondansetron show promise off-label for treating alcohol use disorder.
30 Ιουλ 2021 · UCSF researchers have leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side effects or complications associated with current treatment regimens.
Using 2015-2021 data from the National Survey on Drug Use and Health, we compiled a pool of more than 120,000 women, ages 18-49, who provided information about their drinking habits and, if treatment was desired or recommended, whether they received it.
30 Ιουλ 2020 · A literature review identified several barriers to women seeking help: low perception of a need for treatment; guilt and shame; co-occurring disorders; employment, economic, and health insurance disparities; childcare responsibilities; and fear of child protective services.
